# Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

> **NCT06572618** · PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 27 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Nemtabrutinib
- **PROCEDURE:** Positron Emission Tomography and Computed Tomography Scan
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT06572618
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2027-01-08
- **Final completion:** 2027-01-08
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06572618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06572618, "Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06572618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*